Global Triamcinolone Acetonide Ointment Market Size, Share and Trends Analysis Report, By Type (0.025%, and 0.1%) By Application (Dermatoses, Ulcerative Lesions, and Others), and By Distribution Channel (Hospitals, Drug Stores, and Others), Forecast 2022-2028

The global triamcinolone acetonide ointment market is anticipated to grow at a significant CAGR during the forecast period (2022-2028). The growth of the market is attributed to the rising cases of topical inflammatory dermatoses and ulcerative lesions globally. According to National Eczema Association (NEA), in 202, approximately 31.6 million that is 10.1% people out of the total population of the US have some form of eczema. More than 9.6 million US children under the age of 18 have atopic dermatitis (AD). An estimated 16.5 million of the US adults have an AD that initially began at 2 years of age, with nearly 40% affected by moderate or severe disease.

According to the American Academy of Dermatology (AAD), approximately 7.5 million people in the US have psoriasis. It occurs in all age groups but is primarily seen in adults, with the highest proportion between ages 45 and 65. Approximately 25-30% of people with psoriasis experience joint inflammation that produces symptoms of arthritis. The growing demand for the treatment of these infectious diseases is propelling the growth of the market. There is a surge in demand for topical corticosteroids such as triamcinolone acetonide.

Some major players in the market include G&W laboratories Inc., Lannett Co. Inc., Perrigo Co. PLC, Taro Pharmaceutical Industries Ltd., Mylan NV, Lupin Inc., and Teva Pharmaceutical Industries Ltd. among others. The market players are helping significantly in the growth of the market by the adoption of various strategies including mergers & acquisitions, geographical expansion, partnerships and collaborations, and new product launches, to stay in the competition of the market. For instance, in January 2020, Strides Pharma Science Ltd. announced its step‐down wholly owned subsidiary, Strides Pharma Global Pte. Limited, Singapore, has received tentative approval for Triamcinolone Acetonide Ointment USP, 0.05%. from the US Food & Drug Administration (USFDA).

Market Coverage

• The market number available for – 2022-2028
• Base year- 2021
• Forecast period- 2022-2028
• Segment Covered-
  • By Type
  • By Application
  • By Distribution Channel
• Regions Covered-
  • North America
  • Europe
  • Asia-Pacific
  • Rest of the World
• Competitive Landscape- G&W laboratories Inc., Lannett Co. Inc., Perrigo Co. PLC, Taro Pharmaceutical Industries Ltd., Mylan NV, Lupin ,and Teva Pharmaceutical Industries Ltd. among others.

Key questions addressed by the report

• What is the market growth rate?
• Which segment and region dominate the market in the base year?
• Which segment and region will project the fastest growth in the market?
• How has COVID-19 impacted the market?
  • Deviation from the pre-COVID-19 forecast
  • Most affected region and segment
• Who is the leader in the market?
• How are playersaddressing challenges to sustain growth?
• Where is the investment opportunity?

Global Triamcinolone Acetonide Cream Market Report by Segment

By Type

• 025%
• 1%

By Application

• Dermatoses
• Ulcerative Lesions
• Others

By Distribution Channel

• Hospitals
• Drug Stores
• Others

Global Triamcinolone Acetonide Cream Market Report by Region

North America

• United States
• Canada

Europe

• UK
• Germany
• Italy
• Spain
• France
• Rest of Europe

Asia-Pacific

• China
• India
• Japan
• South Korea
• Rest of Asia-Pacific

Rest of the World

• Latin America

Middle East & Africa